{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:22:45Z","timestamp":1783059765753,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170183"],"award-info":[{"award-number":["82170183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970184"],"award-info":[{"award-number":["81970184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.tranon.2026.102794","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:31:39Z","timestamp":1777660299000},"page":"102794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Eprenetapopt in combination with Palbociclib exerts synthetic lethality in mantle cell lymphoma"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-551X","authenticated-orcid":false,"given":"Ling","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-6090","authenticated-orcid":false,"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.tranon.2026.102794_bib0001","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102794_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the international consensus and 5th World Health Organization classifications of mature B-cell lymphomas","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.tranon.2026.102794_bib0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.tranon.2026.102794_bib0004","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2026.102794_bib0005","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.tranon.2026.102794_bib0006","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.tranon.2026.102794_bib0007","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","article-title":"Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in mantle cell lymphoma: results from the EU-MCL network trials","volume":"38","author":"Khouja","year":"2024","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.tranon.2026.102794_bib0008","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.tranon.2026.102794_bib0009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102794_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"14","key":"10.1016\/j.tranon.2026.102794_bib0011","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.tranon.2026.102794_bib0012","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102794_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31048-7","article-title":"Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246","volume":"8","author":"Haffo","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.tranon.2026.102794_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.417","article-title":"APR-246\/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase","volume":"4","author":"Peng","year":"2013","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.tranon.2026.102794_bib0015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102794_bib0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.tranon.2026.102794_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148141","article-title":"Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade","volume":"132","author":"Ghosh","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"26","key":"10.1016\/j.tranon.2026.102794_bib0018","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fern\u00e0ndez","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102794_bib0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"20","key":"10.1016\/j.tranon.2026.102794_bib0020","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.tranon.2026.102794_bib0021","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/bloodadvances.2022008954","article-title":"Dual targeting of CDK4\/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma","volume":"7","author":"Che","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2026.102794_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216996","article-title":"PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4\/6 inhibitor palbociclib via PLK1 in B-cell lymphoma","volume":"597","author":"Hu","year":"2024","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.tranon.2026.102794_bib0023","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"7658","key":"10.1016\/j.tranon.2026.102794_bib0024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature22797","article-title":"The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival","volume":"546","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.tranon.2026.102794_bib0025","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol."},{"issue":"36","key":"10.1016\/j.tranon.2026.102794_bib0026","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-risk mantle cell lymphoma: definition, current challenges, and management","volume":"38","author":"Jain","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102794_bib0027","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.tranon.2026.102794_bib0028","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.febslet.2014.04.017","article-title":"Mutant p53 reactivation by small molecules makes its way to the clinic","volume":"588","author":"Bykov","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tranon.2026.102794_bib0029","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1038\/s41467-021-27142-6","article-title":"Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)","volume":"12","author":"Degtjarik","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102794_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31048-7","article-title":"Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246","volume":"8","author":"Haffo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102794_bib0031","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102794_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.417","article-title":"APR-246\/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase","volume":"4","author":"Peng","year":"2013","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.tranon.2026.102794_bib0033","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","article-title":"The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ."},{"issue":"10","key":"10.1016\/j.tranon.2026.102794_bib0034","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2026.102794_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.tranon.2026.102794_bib0036","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41375-022-01634-w","article-title":"APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations","volume":"36","author":"Hong","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.tranon.2026.102794_bib0037","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41416-021-01561-0","article-title":"APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-noxa signal in oesophageal squamous cell cancer with TP53 missense mutation","volume":"125","author":"Kobayashi","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102794_bib0038","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.14036","article-title":"Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2\/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells","volume":"174","author":"Ali","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102794_bib0039","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3892\/or.2016.4653","article-title":"PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells","volume":"35","author":"Yoshikawa","year":"2016","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2026.102794_bib0040","article-title":"APR-246 increases tumor antigenicity independent of p53","volume":"7","author":"Michels","year":"2023","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.tranon.2026.102794_bib0041","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-22-0275","article-title":"APR-246 enhances colorectal cancer sensitivity to radiotherapy","volume":"22","author":"Xie","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.tranon.2026.102794_bib0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.radonc.2008.01.001","article-title":"PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status","volume":"86","author":"Supiot","year":"2008","journal-title":"Radiother. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102794_bib0043","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1535-7163.MCT-21-0067","article-title":"SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than TP53 mutation status","volume":"20","author":"Fujihara","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.tranon.2026.102794_bib0044","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/0008-5472.CAN-20-2121","article-title":"Differential regulation of cancer progression by CDK4\/6 plays a Central role in DNA replication and repair pathways","volume":"81","author":"Dai","year":"2021","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102794_bib0045","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bcp.2005.05.012","article-title":"TCR pathway involves ICBP90 gene down\u2011regulation via E2F binding sites","volume":"70","author":"Abbady","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102794_bib0046","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3892\/or.2012.2064","article-title":"UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer","volume":"28","author":"Kofunato","year":"2012","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.tranon.2026.102794_bib0047","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1356-9597.2004.00710.x","article-title":"Down-regulation of nuclear protein ICBP90 by p53\/p21Cip1\/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1\/S transition","volume":"9","author":"Arima","year":"2004","journal-title":"Genes Cells"},{"issue":"8","key":"10.1016\/j.tranon.2026.102794_bib0048","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/15384047.2015.1056411","article-title":"UHRF1 promotes proliferation of gastric cancer via mediating tumor suppressor gene hypermethylation","volume":"16","author":"Zhou","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.tranon.2026.102794_bib0049","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ccell.2019.03.003","article-title":"Defining UHRF1 domains that support maintenance of Human colon cancer DNA methylation and oncogenic properties","volume":"35","author":"Kong","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102794_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13148-018-0462-7","article-title":"Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma","volume":"10","author":"Beck","year":"2018","journal-title":"Clin. Epigenetics"},{"issue":"12","key":"10.1016\/j.tranon.2026.102794_bib0051","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.celrep.2015.03.038","article-title":"UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold","volume":"10","author":"Tian","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.102794_bib0052","article-title":"A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:43:13Z","timestamp":1783057393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S1936523326001312"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102794","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eprenetapopt in combination with Palbociclib exerts synthetic lethality in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102794"}}